Transformation by the R Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation

• Published in: Nature (London) 2012-02, Vol.483 (7390), p.484-488
• Main Authors: Koivunen, Peppi, Lee, Sungwoo, Duncan, Christopher G., Lopez, Giselle, Lu, Gang, Ramkissoon, Shakti, Losman, Julie A., Joensuu, Päivi, Bergmann, Ulrich, Gross, Stefan, Travins, Jeremy, Weiss, Samuel, Looper, Ryan, Ligon, Keith L., Verhaak, Roel G.W., Yan, Hai, Kaelin, William G.
• Format: Article
• Language: English
• ISSN: 0028-0836; 1476-4687
• DOI: 10.1038/nature10898

The identification of succinate dehydrogenase (SDH), fumarate hydratase (FH), and isocitrate dehydrogenase (IDH) mutations in human cancers has rekindled the idea that altered cellular metabolism can transform cells. Inactivating SDH and FH mutations cause the accumulation of succinate and fumarate, respectively, which can inhibit 2-oxoglutarate (2-OG)-dependent enzymes, including the EglN prolyl 4-hydroxylases that mark the HIF transcription factor for polyubiquitylation and proteasomal degradation 1 . Inappropriate HIF activation is suspected of contributing to the pathogenesis of SDH-defective and FH-defective tumors but can suppress tumor growth in some other contexts. IDH1 and IDH2, which catalyze the interconversion of isocitrate and 2-OG, are frequently mutated in human brain tumors and leukemias. The resulting mutants display the neomorphic ability to convert 2-OG to the R-enantiomer of 2-hydroxyglutarate (R-2HG) 2 , 3 . Here we show that R-2HG, but not S-2HG, stimulates EglN activity leading to diminished HIF levels, which enhances the proliferation and soft agar growth of human astrocytes.